A three-judge panel of the 2nd U.S. Circuit Court of Appeals in Manhattan said a lower court judge acted properly in imposing the ban and ordering Shkreli to repay $64.6 million because of his antitrust violations.
For Sandoz, Monday’s deal with Coherus represents its first major contract since spinning out of Novartis in October 2023.
While gene therapies for treating sickle cell disease are promising, they will only be cost effective in the U.S. if priced below $2 million, according to a new modeling analysis.
Despite a new safety warning from the U.S. Food and Drug Administration, J&J still expects its cancer treatment to hit peak sales.
The deal will bolster nthye French company’s drug development portfolio with an experimental treatment for a rare genetic disease.
ReutersThe agency stated that companies will be required to add a serious warning on the prescribing information for cancer therapies known as CAR-T, made by Gilead Sciences, Johnson & Johnson, Novartis and others.
Clinical trial technology leader amplifies its dedication to empowering researchers and revolutionizing the clinical trial landscape.
Saturday’s readout, which were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, could position BMS to challenge Merck’s dominant PD-1 blocker Keytruda.
Johnson & Johnson’s small molecule FGFR kinase inhibitor is now indicated for patients with susceptible FGFR3 mutations who progressed after at least one line of systemic therapy.
The regulator concluded that Prolia (denosumab) increases the risk of severe hypocalcemia, which may result in hospitalization and could trigger life-threatening events or even lead to death.
